The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: (link sends e-mail)

Study Name on (link is external)
Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients (PsAer-IgY)
Study DrugAvian Polyclonal Anti-Pseudomonas Antibodies (IgY)
Type of Study DrugAnti-infective
Study TitlePhase III Study to Evaluate Clinical Efficacy and Safety of Avian Polyclonal Anti-Pseudomonas Antibodies (IgY) in Prevention of Recurrence of Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients
Study Phase3
Study SponsorMukoviszidose Institut gGmbH

Link on (link is external)

Additional information: (in German language)

Participating ECFS-CTN sitesBelgium: Leuven
Germany: Berlin, Frankfurt, Hannover, Cologne
Italy: Firenze, Genua, Rome, Verona
Spain: Barcelona
Sweden: Stockholm
Age5 years and older